Cargando…

The Impact of Oral-Gut Inflammation in Cerebral Palsy

Background: Oral-gut inflammation has an impact on overall health, placing subjects at risk to acquire chronic conditions and infections. Due to neuromotor disturbances, and medication intake, cerebral palsy (CP) subjects present intestinal constipation, impacting their quality of life (QOL). We aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferreira, Ana Cristina Fernandes Maria, Eveloff, Ryan J., Freire, Marcelo, Santos, Maria Teresa Botti Rodrigues
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953843/
https://www.ncbi.nlm.nih.gov/pubmed/33717115
http://dx.doi.org/10.3389/fimmu.2021.619262
_version_ 1783663994982105088
author Ferreira, Ana Cristina Fernandes Maria
Eveloff, Ryan J.
Freire, Marcelo
Santos, Maria Teresa Botti Rodrigues
author_facet Ferreira, Ana Cristina Fernandes Maria
Eveloff, Ryan J.
Freire, Marcelo
Santos, Maria Teresa Botti Rodrigues
author_sort Ferreira, Ana Cristina Fernandes Maria
collection PubMed
description Background: Oral-gut inflammation has an impact on overall health, placing subjects at risk to acquire chronic conditions and infections. Due to neuromotor disturbances, and medication intake, cerebral palsy (CP) subjects present intestinal constipation, impacting their quality of life (QOL). We aimed to investigate how oral inflammatory levels predicted gut phenotypes and response to therapy. Methods: A total of 93 subjects aging from 5 to 17 years were included in the study, and assigned into one of the 4 groups: CP with constipation (G1, n = 30), CP without constipation (G2, n = 33), and controls without CP with constipation (G3, n = 07) and without CP and without constipation (G4, n = 23). In addition to characterizing subjects' clinical demographics, medication intake, disease severity levels, salivary cytokine levels [TNF-α, interleukin (IL)-1β, IL-6, IL-8, IL-10], and Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD). Statistical significance was evaluated by Shapiro-Wilks, Student's T-Test, ANOVA, and ANCOVA analysis. Results: Salivary proinflammatory cytokines were highly correlated with the severe form of gut constipation in G1 (P < 0.001), and out of all cytokines IL-1β levels demonstrated highest correlation with all gut constipation (P < 0.05). A significant relationship was found between the type of medication, in which subjects taking Gamma-Aminobutyric Acid (GABA) and GABA+ (GABA in association with other medication) were more likely to be constipated than the other groups (P < 0.01). Cleary salivary inflammatory levels and gut constipation were correlated, and impacted QOL of CP subjects. G1 presented a lower QOL mean score of CPCHILD (49.0 ± 13.1) compared to G2 (71.5 ± 16.7), when compared to G3 (88.9 ± 7.5), and G4 (95.5 ± 5.0) (P < 0.01). We accounted for gingival bleeding as a cofounder of oral inflammation, and here were no differences among groups regarding gender (P = 0.332) and age (P = 0.292). Conclusions: Collectively, the results suggest that saliva inflammatory levels were linked to gut constipation, and that the clinical impact of medications that controlled gut was reliably monitored via oral cytokine levels, providing reliable and non-invasive information in precision diagnostics.
format Online
Article
Text
id pubmed-7953843
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79538432021-03-13 The Impact of Oral-Gut Inflammation in Cerebral Palsy Ferreira, Ana Cristina Fernandes Maria Eveloff, Ryan J. Freire, Marcelo Santos, Maria Teresa Botti Rodrigues Front Immunol Immunology Background: Oral-gut inflammation has an impact on overall health, placing subjects at risk to acquire chronic conditions and infections. Due to neuromotor disturbances, and medication intake, cerebral palsy (CP) subjects present intestinal constipation, impacting their quality of life (QOL). We aimed to investigate how oral inflammatory levels predicted gut phenotypes and response to therapy. Methods: A total of 93 subjects aging from 5 to 17 years were included in the study, and assigned into one of the 4 groups: CP with constipation (G1, n = 30), CP without constipation (G2, n = 33), and controls without CP with constipation (G3, n = 07) and without CP and without constipation (G4, n = 23). In addition to characterizing subjects' clinical demographics, medication intake, disease severity levels, salivary cytokine levels [TNF-α, interleukin (IL)-1β, IL-6, IL-8, IL-10], and Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD). Statistical significance was evaluated by Shapiro-Wilks, Student's T-Test, ANOVA, and ANCOVA analysis. Results: Salivary proinflammatory cytokines were highly correlated with the severe form of gut constipation in G1 (P < 0.001), and out of all cytokines IL-1β levels demonstrated highest correlation with all gut constipation (P < 0.05). A significant relationship was found between the type of medication, in which subjects taking Gamma-Aminobutyric Acid (GABA) and GABA+ (GABA in association with other medication) were more likely to be constipated than the other groups (P < 0.01). Cleary salivary inflammatory levels and gut constipation were correlated, and impacted QOL of CP subjects. G1 presented a lower QOL mean score of CPCHILD (49.0 ± 13.1) compared to G2 (71.5 ± 16.7), when compared to G3 (88.9 ± 7.5), and G4 (95.5 ± 5.0) (P < 0.01). We accounted for gingival bleeding as a cofounder of oral inflammation, and here were no differences among groups regarding gender (P = 0.332) and age (P = 0.292). Conclusions: Collectively, the results suggest that saliva inflammatory levels were linked to gut constipation, and that the clinical impact of medications that controlled gut was reliably monitored via oral cytokine levels, providing reliable and non-invasive information in precision diagnostics. Frontiers Media S.A. 2021-02-25 /pmc/articles/PMC7953843/ /pubmed/33717115 http://dx.doi.org/10.3389/fimmu.2021.619262 Text en Copyright © 2021 Ferreira, Eveloff, Freire and Santos. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Ferreira, Ana Cristina Fernandes Maria
Eveloff, Ryan J.
Freire, Marcelo
Santos, Maria Teresa Botti Rodrigues
The Impact of Oral-Gut Inflammation in Cerebral Palsy
title The Impact of Oral-Gut Inflammation in Cerebral Palsy
title_full The Impact of Oral-Gut Inflammation in Cerebral Palsy
title_fullStr The Impact of Oral-Gut Inflammation in Cerebral Palsy
title_full_unstemmed The Impact of Oral-Gut Inflammation in Cerebral Palsy
title_short The Impact of Oral-Gut Inflammation in Cerebral Palsy
title_sort impact of oral-gut inflammation in cerebral palsy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953843/
https://www.ncbi.nlm.nih.gov/pubmed/33717115
http://dx.doi.org/10.3389/fimmu.2021.619262
work_keys_str_mv AT ferreiraanacristinafernandesmaria theimpactoforalgutinflammationincerebralpalsy
AT eveloffryanj theimpactoforalgutinflammationincerebralpalsy
AT freiremarcelo theimpactoforalgutinflammationincerebralpalsy
AT santosmariateresabottirodrigues theimpactoforalgutinflammationincerebralpalsy
AT ferreiraanacristinafernandesmaria impactoforalgutinflammationincerebralpalsy
AT eveloffryanj impactoforalgutinflammationincerebralpalsy
AT freiremarcelo impactoforalgutinflammationincerebralpalsy
AT santosmariateresabottirodrigues impactoforalgutinflammationincerebralpalsy